Kexing
Biopharm

KEXING BIOPHARM CO., LTD.

Tel:0086-531-55763601/02/03　　E-mail：sales@kexing.com
Website:www.kexingbiopharm.com

Precise Products
Predictable Effects
Health Protection

Kexing
Biopharm

Kexing Biopharm

A leader in China recombinant protein the rapeutics industry

Kexing Biopharm (Stock Code: 688136) is a leading multinational biopharmaceutical company specializing in the research, manufacture, and commercialization of innovative medicines combining recombinant proteins, antibodies, and next generation cell and gene therapies. Harnessing proprietary technology platforms, Kexing pioneers novel targeted biological therapies and advanced drug delivery systems to address critical unmet needs in oncology, autoimmune and infectious diseases, making transformative impact on patients.Driven by a dual strategic focus on breakthrough innovation and global outreach, Kexing is committed to becoming a world-class leader in bringing high-quality pharmaceutical solutions to patients worldwide.

Kexing Biopharm offers a diversified portfolio of 30 innovative products, including drugs "Human Erythropoietin Injection (EPOSINO)", "Human Interferon α1b for Injection (SINOGEN)" and "Human Granulocyte Colony-stimulating Factor Injection (WHITE-C)"; microecological agents, notably "Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO)"; targeted drugs, such as "Albumin-bound Paclitaxel (Apexelsin)" and "Infliximab for Injection (Reminton)". Our core products outperform competitors' options in China, with SINOGEN and EPOSINO leading positions in their respective therapeutic categories, consistently securing the top two rankings in market share. Our products are supplied to over 20,000 sales terminals across China, including over 8,000 hospitals, 7,700 third-party terminals, and over 3,000 pharmacies. In addition, we have established 6 overseas subsidiaries, which have acquired market access and achieved sales in over 70 countries and regions such as the European Union, Brazil, Philippines and Indonesia. In recent years, we also have created a high-quality biopharmaceuticals overseas platform based on the concept of "Global Product Selection + Global Product Coverage", and secured commercial partnerships with numerous renowned pharmaceutical companies worldwide by leveraging its global marketing infrastructure, targeted market penetration strategies, and commitment to delivering premium-quality products and services.

Kexing Biopharm operates multiple R&D centers, such as the Shenzhen Medical Research Institute, the Shandong R&D Center and the Guangzhou R&D Center. It boasts an R&D team of nearly 200 members, with over 60% holding master's degrees or higher. At present, it has obtained 65 patents. The Company has established a complete drug R&D and innovation system with three major biotechnology systems: Prokaryotic cell technology, eukaryotic cell technology, and viable bacteria technology. Depending on these systems, it has built several leading technology platforms worldwide, such as KX-FUSION Fusion Protein Technology Platform, KX-BODY Antibody Technology Platform, K'Exosome Delivery Technology Platform, Vector Vaccine Technology Platform, and Microecological Agent R&D and Industrialization Technology Platform.

The Company focuses on biopharmaceuticals and implements a strategic R&D plan that enables a tiered, serial, and graduated product portfolio. Our short-term efforts are concentrated on in-depth development around new formulations, new indications and long-acting effects for recombinant protein therapeutics. In the medium and long term, we focus on fields such as oncology, immunology and degenerative diseases, with plans to develop new antibodies, proteins and nucleic acid drugs. It boasts robust pipelines of innovative drugs and dozens of projects currently under development, including GB05 Human Interferon α1b Inhalation Solution (Phase III clinical trial), GB-K02 Long-acting Human Granulocyte Colony-stimulating Factor Injection (Phase III clinical trial), GB08 Long-acting Growth Hormone (completed Phase I clinical trial), GB10 (target: VEGF/ANG-2) for fundus diseases, GB12 (target: IL-4R/IL-31(R)) for atopic dermatitis, GB18 (target: GDF-15) for cancer cachexia, GB23 (target: IFN/GPC3/PD1) for solid tumors, GB24 (target: TL1A, bispecific antibody) for inflammatory bowel diseases, and GB25 (tri-specific antibody) for colorectal cancer.

Following the mission of "Precise Products, Predictable Effects, Health Protection", we are devoted to providing patients with biotechnology and becoming the leader in high-quality biologics!

Kexing
Biopharm

WHITE-C

Human Granulocyte Colony-stimulating Factor Injection

Kexing Biopharm

A clinical first-line drug for prevention and treatment of neutropenia after tumor chemoradiotherapy

Indications

- Neutropenia due to cancer chemotherapy and other reasons;
- Neutropenia due to chemotherapy for acute leukemia.

Precise Products Predictable Effects Health Protection

WHITE-C

CLINICAL

Since its introduction into the market in 2001, WHITE-C has been clinically applied for more than 20 years, with a wide range of evidence-based applications, topping the list of domestic similar products in terms of export volume. As strict in-house control quality standards are followed, WHITE-C is not only in line with Chinese Pharmacopoeia, but also European Pharmacopoeia.



Advantages

- Early introduction into the market, clinically applied for more than 20 years, a relatively wide range of evidence-based applications;
- Registered into and sold in 22 countries and regions.

Commonly used departments

- Oncology
- Hematology
- Radiotherapy
- Gynecology
- Breast
- Thoracic medicine and other departments related to tumor chemoradiotherapy

Strength

- 75ug/0.5ml/vial(vial)
- 150ug/0.5ml/vial(vial)
- 300ug/ml/vial(vial)
- 75ug/0.5ml/syringe (pre-lled syringe)
- 150ug/0.5ml/syringe (pre-lled syringe)
- 150ug/ml/syringe (pre-lled syringe)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

APEXELSIN

Paclitaxel For Injection
(Albumin Bound)

Kexing Biopharm

Blockbuster drugs in tumor chemotherapy, Approved for listing in China and the European Union

Indications

- Albumin-bound paclitaxel monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated;
- Albumin-bound paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas;
- Albumin-bound paclitaxel in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

Precise Products Predictable Effects Health Protection

APEXELSIN

Albumin-bound paclitaxel takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility, featured by "Three Highs and One Low", i.e. high dose, high distribution in tumor tissue, high efficacy, and low toxicity. Albumin-bound paclitaxel is recommended by the NCCN and CSCO guidelines for the treatment of breast cancer. It is the only product in China that is applied simultaneously in China, the United States, and the European Union, and has obtained the Chinese marketing license and the EU approval for marketing as well.

Advantages

- It is a high-end complex drug product enhanced by nanotechnology;
- The efficacy and safety of albumin-bound paclitaxel are superior to those of solvent-based paclitaxel and docetaxel, and it is the optimal choice for breast cancer treatment;
- Apexelsin has obtained the Chinese marketing license and the EU approval for marketing as well.

Commonly used departments

- Oncology Department
- Pancreatology Department
- Gynaecology
- Hepatobiliary Surgery
- Respiratory Medicine

Strength

- 100 mg/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ARKETIN

Bevacizumab Injection

Kexing Biopharm

Fully humanized monoclonal antibody biosimilar as a broad-spectrum antitumor drug

Indications

- Metastatic colorectal cancer;
- Advanced, metastatic, or recurrent non-small cell lung cancer;
- Recurrent glioblastoma;
- Epithelial ovarian cancer, fallopiantube cancer, or primary peritoneal cancer;
- Cervical cancer.

Precise Products Predictable Effects Health Protection

ARKETIN

ARKETIN

Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb), specifically binds to VEGF to prevent VEGF from binding to its receptor, thereby reducing neovascularization, inducing degeneration of existing blood vessels and inhibiting tumor growth. As a broad-spectrum anti-tumor agent, bevacizumab is a standard regimen recommended in treatment guidelines for various malig nancies worldwide. Since entering the market, its efficacy and safety have been widely demonstrated in clinical practice.

Advantages

- As a broad-spectrum anti-tumor agent, it is recommended as a standard regimen in treatment guidelines for various malignancies worldwide;
- It is subject to several rigorous and comprehensive head-to-head studies with the originator product (Avastin by Roche);
- It is suitable for the extended application for all 8 indications of the originator product.

Commonly used departments

- Oncology
- Thoracic Surgery
- Gynecology
- Respiratory Medicine
- Anorectal Medicine

Strength

- 100 mg/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ACURVIGTA
Trastuzumab Injection

Kexing Biopharm

Drug for full-course treatment of HER2+ breast cancer

Indications

- HER2-positive metastatic breast cancer;
- Early-stage breast cancer and metastatic gastric cancer.

Precise Products Predictable Effects Health Protection

ACURVIGTA

Trastuzumab can bind to human epidermal growth factor receptor 2 (HER2) receptors with high specificity, prevent EGF from rebinding to HER2, and then delay the growth of tumor cells. It is widely used in the treatment for metastatic breast cancer, early-stage breast cancer and metastatic gastric cancer. The brand-name product of trastuzumab was launched in the United States in 1998. With its excellent clinical profiles, trastuzumab with expanded indications has become a drug used in the full treatment course of HER2+ breast cancer with great significance in this field.

Advantages

- Trastuzumab is the first innovative drug targeting HER2+ breast cancer worldwide and the cornerstone of HER2+ breast cancer treatment;
- A series of immunogenicity, pharmaceutical, non-clinical and clinical comparative studies have shown that it is highly consistent with the brand-name product of trastuzumab, with equivalent clinical efficacy, similar safety, covering all indications approved for the brand-name product in China;
- 150 mg/vial, without preservatives; use immediately after preparation with any unused portion discarded to ensure the safe medication for patients and standardized management of drug use and benefit both patients and medical staff.

Commonly used departments

- Oncology
- Breast Surgery
- Gastrointestinal Surgery

Strength

- 150 mg/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ALCOMHER
Neratinib Maleate Tablets

Kexing Biopharm

New drug for extended adjuvant therapy of HER2+ breast cancer worldwide

Indications

For extended adjuvant therapy after adjuvant trastuzumab-based therapy in patients with early-stage HER2-positive breast cancer.

Precise Products Predictable Effects Health Protection

ALCOMHER

ALCOMHER

Neratinib Maleate Tablets is an oral irreversible small molecule pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI) indicated for the extended adjuvant treatment of adult patients with early-stage HER2+ breast cancer after adjuvant trastuzumab-based therapy and the treatment of adult patients with metastatic advanced HER2+ breast cancer who have received two or more treatment regimens, recommended by many authoritative guidelines worldwide.

Advantages

- Oral TKI used for extended adjuvant therapy of HER2+ breast cancer worldwide, with a wide range of targets;
- Recommended by authoritative guidelines worldwide including 2020 NCCN Guidelines for Breast Cancer, ASCO, ESMO, Guidelines of China Anti-Cancer Association (CACA) for Breast Cancer, and Guidelines of Chinese Society Of Clinical Oncology (CSCO) for Breast Cancer as the drug for extended adjuvant therapy;
- Sequential use of neratinib can significantly reduce the risk of recurrence in patients with early-stage HER2+ breast cancer after adjuvant trastuzumab-based therapy.

Commonly used departments

- Oncology
- Breast Surgery

Strength

- 40mg,180 tablets/bottle

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

BAIRUIAN

Eribulin Mesylate Injection

Kexing Biopharm

The synthesis is extremely difficult and is known as the "mount everest" in the field of chemical and pharmaceutical synthesis



Indications

- For the treatment of patients with metastatic breast cancer who have received at least two previous treatment regimens, including anthracycline and taxane.
- For the treatment of patients with unresectable or metastatic liposarcoma who have been treated with anthracycline-containing drugs.

Precise Products Predictable Effects Health Protection

BAIRUIAN

BAIRUIAN

Eribulin Mesylate injection is indicated for patients with locally advanced or metastatic breast cancer who have previously received at least two chemotherapy regimens. As a new choice for yew and anthracycline resistance, it enables drug-resistant patients to achieve overall survival benefits, and is the preferred drug for advanced breast cancer.

As the most difficult compound to synthesize in the synthetic world, the compound contains 19 chiral centers, theoretically 524,287 aberrations, and more than 65 synthetic steps, which is extremely difficult to synthesize, and is known as the "Everest" in the field of chemical and drug synthesis, with few competitors and good market prospects.



Advantages

- It has been approved for marketing by China NMPA and the U.S. FDA.
- The synthesis is extremely difficult and is known as the "Mount Everest" in the field of chemical and pharmaceutical synthesis;
- With a unique anti-tumor mechanism, a single drug can extend the survival time of advanced breast cancer patients and significantly improve the quality of life of patients.

Commonly used departments

- Oncology department
- Gynecology

Strength

- 1mg/2mL

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

AIRKEFAY
Sorafenib Tablets

Kexing Biopharm

The world's first approved multi target anti-cancer drug

Indications

- Hepatocellular Carcinoma

Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

- Differentiated Thyroid Carcinoma

Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic.progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Precise Products Predictable Effects Health Protection

AIRKEFAY

Sorafenib is an oral multi-target receptor tyrosine kinase inhibitor, which can block tumor cell proliferation, inhibit angiogenesis, and induce tumor cell apoptosis. It has good anti-tumor activity, and is mainly used in the treatment of advanced renal cell carcinoma. At present, it is also the first molecular targeted drug with good efficacy in the treatment of liver cancer.

Advantages

- An oral multi-target, multi-kinase inhibitor;
- Sorafenib exerts dual effects of anti-angiogenesis and anti-tumor cell proliferation at the same time;
- Sorafenib Tablets have been approved for marketing by the NMPA in 2021 and by the FDA in 2022.

Commonly used departments

- Oncology department
- Department of hepatology
- Thyroid surgery
- Respiratory medicine
- Nephrology department

Strength

- 200mg/tablet

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

AUBERVIS
Palbociclib Capsules

Kexing Biopharm

The world's first CDK4/6 targeted inhibitor approved for HR+/ HER2-type locally advanced or metastatic breast cancer

Indications

- Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:
  - in combination with an aromatase inhibitor;
  - in combination with fulvestrant in women who have received prior endocrine therapy .
- In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

Precise Products Predictable Effects Health Protection

AUBERVIS

Breast cancer is the most common malignant tumor in women, of which HR+/HER2- breast cancer accounts for more than 60%. Palbociclib is the world's first approved CDK4/6 inhibitor, and its emergence opens a new era of endocrine therapy for HR+/HER2- advanced breast cancer. Compared with previous endocrine therapy alone, the combination of Palbociclib significantly extends the survival time of patients.

Advantages

- Palbociclib is an oral small molecule cyclin-dependent kinase (CDK4/6) inhibitor and is the first CDK4/6 inhibitor approved globally for HR+/ HER2-locally advanced or metastatic breast cancer;
- Complete drug specifications, in line with China and the US declaration standards, has been approved in Chinese , and has been submitted NDA in the US.

Commonly used departments

- Oncology department
- Gynecology

Strength

- 75mg/capsule
- 100mg/capsule
- 125mg/capsule

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

AURAVENE

Olaparib Tablets

Kexing Biopharm

The first PARP inhibitor has the potential to be a broad-spectrum antitumor drug

Indications

- This product is indicated for maintenance treatment in newly treated adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer carrying germ line or somatic BRCA mutations (gBRCAm or sBRCAm) after first-line platinum-containing chemotherapy has achieved complete or partial response;
- Maintenance therapy in adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after achieving complete or partial response to platinum-containing chemotherapy.

Precise Products Predictable Effects Health Protection

AURAVENE

Olaparib Tablets, as a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor,by inhibiting the activity of PARP enzyme, the DNA repair ability of tumor cells is hindered, which leads to the death of tumor cells.Olaparib Tablets is initially indicated for BRCA-mutated advanced ovarian cancer, and subsequently expanded to ovarian cancer, breast cancer, pancreatic cancer, prostate cancer and other malignancies. It is a first-line therapeutic agent for breast cancer and a first-line maintenance therapy for ovarian cancer recommended by the NCCN clinical guidelines.

Advantages

- It has been approved for marketing by China NMPA.
- The first PARP inhibitor has the potential to be a broad-spectrum antitumor drug.
- Olaparib tablets are produced by hot melt extrusion technology, which is a high-end preparation.

Commonly used departments

- Oncology department
- Gynecology

Strength

- 100mg/tablet
- 150mg/tablet

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

APALUTAMIDE TABLETS

Kexing Biopharm

The world's first approved drug for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC)

Indications

- Metastatic castration-sensitive prostate cancer (mCSPC)
- Non-metastatic castration-resistant prostate cancer (nmCRPC)

Precise Products Predictable Effects Health Protection

APALUTAMIDE

Apalutamide is a new generation of orally available androgen receptor (AR) inhibitor that can directly bind to the ligand-binding domain of AR, inhibit AR nuclear translocation and DNA binding, and block AR-mediated transcription, thereby reducing tumor cell proliferation and promoting apoptosis, thereby reducing tumor volume.
Apalutamide is the world's first drug for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and the first new anti-tumor drug approved for marketing based on the clinical endpoint of metastasis-free survival.

Advantages

- The world's first approved drug for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC), filling the gap in the treatment of this stage.
- It is also approved for metastatic castration-sensitive prostate cancer (mCSPC) and other conditions, playing a role in key stages of prostate cancer progression and providing patients with continuous treatment options.
- It is an oral preparation, administered once a day, without the need for frequent injections or hospitalization, facilitating long-term home-based treatment for patients and improving their quality of life.

Commonly used departments

- Oncology
- Urology

Strength

- 60mg/tablet

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

CLOBICO

Combined Clostridium Butyricum and Bifidobacterium Capsule, Live

Kexing Biopharm

An exclusive probiotic product available to the old, the young, as well as pregnant and lying-in women

Indications

• Acute and chronic diarrhea caused by acute non-specic infection, intestinal ora imbalance caused by antibiotics, chronic liver disease and other reasons, and related acute and chronic diarrhea and dyspepsia.

Precise Products Predictable Effects Health Protection

CLOBICO

CLOBICO

Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO) is a combination of clostridium butyricunm and bifidobacterium infantis. Both bacterial strains are dominant in autochthonous intestinal flora and can synergistically promote the growth of each other. With proven immunoregulatory effect and a wide range of clinical applications and evidence-based support, it is a probiotic that is explicitly approved for use by the old, the young, as well as pregnant women before and after delivery, in the package insert.



Advantages

- The first-in-class drug of biopharmaceuticals, exclusive formula of autochthonous flora, a combination of autochthonous flora producing butyric acid and lactic acid.
- A widely used probiotic product available to the old, the young as well as pregnant and lying-in women, filling the gap in clinical medication.
- It has long been ranked among the top three in the "Diarrhea Drug List" in China's online pharmaceutical sales channels.

Commonly used departments

- Pediatric Gastroenterology
- Pediatric Pneumology
- Gastroenterology
- Neonatology
- Infectious Diseases
- Obstetrics And Gynecology
- Geriatrics And Oncology

Strength

- 500 mg/sachet
- 420 mg/capsule

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

PANTOPRAZOLE SODIUM FOR INJECTION

Kexing Biopharm

Selective long-acting proton pump inhibitors

Indications

- It is used for treating acid-related diseases of the stomach and intestine.
- It is used for treating adults for:

- Reffux oesophagitis. An inffammation of your oesophagus (the tube which connects your throat to your stomach) accompanied by the regurgitation of stomach acid.
- Stomach and duodenal ulcers.
- Zollinger-Ellison-Syndrome and other conditions producing too much acid in the stomach.

Precise Products Predictable Effects Health Protection

PANTOPRAZOLE SODIUM

PANTOPRAZOLE SODIUM

Pantoprazole Sodium for injection is a selective, long-acting proton pump inhibitor that effectively inhibits gastric acid secretion by activating proton transfer enzymes on the associated microtubules in the apical layer of parietal cells and on the tubular vesicles within the cytoplasm. Pantoprazole sodium for injection is currently widely marketed worldwide.

Advantages

- Works immediately through IV delivery for powerful acid suppression especially in critical cases.
- It avoids the "first-pass effect" and interference from food or gastric emptying time associated with oral intake.
- Provides the only effective way to medicate patients who can't swallow, are unconscious, or post-surgery.

Commonly used departments

- Gastroenterology
- ICU
- Gastrointestinal Surgery
- Oncology (Gastric mucosal injury)
- Cardiology Departments (Gastric mucosal injury)

Strength

- 40 mg powder for solution for injection

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

REMINTON
Infliximab for Injection

Kexing Biopharm

The first approved biosimilar to Infliximab in China

Indications

- Crohn's disease in adults and children over 6 years of age;
- Stulizing Crohn's disease;
- Ulcerative colitis in adults;
- Ankylosing spondylitis;
- Rheumatoid arthritis, and psoriasis.

Precise Products Predictable Effects Health Protection

REMINTON

REMINTON

Reminton, a recombinant anti-TNF-a monoclonal antibody was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Reminton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.

Advantages

- The first approved biosimilar to Infliximab in China.
- Its efficacy and safety are equivalent to those of the originator product (Remicade® by Johnson & Johnson and Merck).
- It has been approved for marketing in many countries around the world.

Commonly used departments

- Rheumatology and Immunology
- Gastroenterology
- Dermatology
- Anorectal Surgery
- Pediatrics

Strength

- 100 mg/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

AHRASIN

Adalimumab
Solution for Injection

Kexing Biopharm

As a blockbuster drug in the field of autoimmune diseases, Adalimumab has topped the list of the world's best-selling drugs for many consecutive years



Indications

- Rheumatoid Arthritis
- Ankylosing spondylitis
- Psoriasis
- Crohn's disease
- Uveitis
- Plaque psoriasis in children
- Crohn's disease in children
- Polyarticular juvenile idiopathic arthritis

Precise Products Predictable Effects Health Protection

AHRASIN

AHRASIN

Adalimumab is a fully human anti-tumor necrosis factor-a (TNF-a) monoclonal antibody, Excessive inflammation in a variety of immune-mediated diseases in humans are associated with TNF-a.

It can be selectively related to TNF-a Molecule binding prevents it from attaching to healthy cells, thereby reducing excessive TNF-a Damage caused. Based on this principle, Adalimumab can be used to treat a variety of immune mediated diseases.



Advantages

- Fully human anti-tumor necrosis factor-a (TNF-a) monoclonal antibody, a biosimilar drug of HUMIRA.
- Launched in 2019, the second domestic adalimumab biosimilar drugs in China.
- The prescription has independent intellectual property rights and has been authorized by Chinese and Russian patents.
- Domestic adalimumab sales of the highest.

Commonly used departments

- Rheumatology and immunology Department
- Gastroenterology
- Dermatology
- Ophthalmology

Strength

- 0.8ml: 40mg

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

EPOSINO

Human Erythropoietin Injection

Kexing Biopharm

A clinical first-line drug and an industry-leading product for the treatment of anemia in many fields



Indications

- Anemia caused by renal dysfunction, including dialysis and non-dialysis patients;
- Perioperative erythrocyte mobilization;
- Anemia caused by chemotherapy for non-myeloid malignancies.

Precise Products Predictable Effects Health Protection

EPOSINO

EPOSINO

EPOSINO is the first batch of human erythropoietin approved for R&D in China and obtained the New Drug Certificate and NMPA's official approval number. It is complete in dosage forms and strengths and firstly administrated by pre-filled syringes for more convenient clinical drug selection. As an industry-leading product, it has been accessed into and sold in more than 30 countries, including Brazil, Philippines and Indonesia.

Advantages

- Patented formula free of human albumin.
- EPOSINO ranks second in Chinese erythropoietin.
- Registered and sold in more than 30 countries and regions, topping the list of similar products in terms of export volume.

Commonly used departments

- Kidney Diseases (Renal Anemial)
- Oncology (Tumor-associated Anemial)
- Surgery (Perioperative Anemial)
- Hematology

Strength

- 2000IU/ml/vial(PFS)
- 6000IU/ml/vial(PFS)
- 4000IU/ml/vial(PFS)
- 10000IU/ml/vial(PFS)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

EXLIMCON
Sevelamer
Carbonate Tablets

Kexing
Biopharm

Guidelines recommend first-line drugs for the clinical treatment of hyperphosphatemia in adults with chronic kidney disease (CKD)

Indications

Sevelamer carbonate tablets are a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.

Precise Products Predictable Effects Health Protection

EXLIMCON

EXLIMCON

In recent years, the incidence and hospitalization rate of chronic kidney disease (CKD), especially end-stage renal disease, have increased significantly, seriously threatening human health. Sevelamer carbonate is a new generation of non-absorbable phosphate binding crosslinked polymers, which can reduce the concentration of phosphate in serum by binding to phosphate in digestive tract and reducing its absorption. It is clinically used to control hyperphosphatemia in adult patients with chronic kidney disease (CKD) undergoing dialysis treatment and is the first-line drug recommended by clinical treatment guidelines.

Advantages

- It has a unique mechanism of action, which can effectively reduce blood phosphorus and achieve the purpose of early intervention;
- As a non-calcium-phosphorus binding agent, Sevelamer can effectively avoid the increase of calcium load, thereby delaying the progression of vascular calcification and renal failure;
- Sevelamer does not contain other metal components and is not absorbed into the blood, avoiding the risk of accumulation.
- The formulation products have obtained official approvals in China, Europe, the United States and other markets.

Commonly used departments

- Nephrology department
- Hemodialysis room

Strength

- 800mg/Film-coated Tablets

Kexing
Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

SINOGEN

SINOGEN

Human Interferon α1b for Injection

Kexing Biopharm

A classic broad-spectrum antiviral drug and an industry-leading product

Indications

- Viral diseases and some malignant tumors;
- Chronic hepatitis B, hepatitis C and hairy cell leukemia;
- Viral diseases such as herpes zoster, condyloma acuminata, epidemic hemorrhagic fever and respiratory syncytial virus pneumonia in children;
- Malignant tumors such as chronic myelogenous leukemia, melanoma and lymphoma.

Precise Products Predictable Effects Health Protection

SINOGEN

SINOGEN

The first α1b interferon in the world using Chinese gene for cloning and expression, which makes its clinical use consistent with the natural antiviral status of Chinese population. It has high purity, good stability, stronger antiviral activity and immune regulation ability, and lower neutralization antibody production rate and drug antigenicity.

The emergence of SINOGEN has broken the monopoly situation of interferon products from Europe and America in China. The birth of SINOGEN has brought about a brand-new biotechnological revolution, which is a milestone of epoch-making significance to Kexing or even the entire R&D field of biopharma-ceutical in China.

Advantages

- The first genetically engineered new drug in China;
- Broad-spectrum antiviral, anti-tumor, immunity-enhancing effect;
- Complete in strengths (6 product strengths), extensive indications;
- Interferon subtypes with pediatric indications labeled.

Commonly used departments

- Pediatric
- Respiratory Medicine
- Hepatology
- Infectious Disease
- Dermatology
- Gynecology
- Hematology
- Oncology

Strength

- 10ug/vial
- 20ug/vial
- 30ug/vial
- 40ug/vial
- 50ug/vial
- 60ug/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ONRADIVIR TABLETS

Kexing Biopharm

The world's first approved influenza RNA polymerase PB2 protein inhibitor

Indications

- It is indicated for the treatment of uncomplicated influenza A in adult patients, excluding those at high risk of influenza-related complications.

Precise Products Predictable Effects Health Protection

ONRADIVIR

ONRADIVIR

Onradisvir tablets are the world's first approved inhibitor of the influenza RNA polymerase PB2 protein, offering a novel treatment option for influenza.

They exert their antiviral effects by binding to the PB2 subunit of the influenza virus RNA polymerase, inhibiting transcription and replication of the viral genome. This mechanism of action differs from other anti-influenza drugs (such as oseltamivir and mabaloxavir) in that they primarily target neuraminidase (NA) or cap-dependent endonuclease (PA).

Advantages

- Innovative: Targeting the PB2 subunit of the influenza A virus RNA polymerase, it blocks the polymerase to stop virus replication directly.
- Fast: Relieves systemic flu symptoms within 18 hours, shortening the duration of illness.
- Potent: Offers strong antiviral activity, rapidly eliminating the virus within 24 hours.
- Low Resistance: Effectively works against drug-resistant strains and highly pathogenic avian influenza viruses.

Commonly used departments

- Infectious Diseases
- Fever Clinic
- Emergency Department
- Influenza A

Strength

- 0.2g/tablet

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

OSELTAMIVIR PHOSPHATE

Kexing Biopharm

Classic anti-influenza virus drug oral suspension



Indications

- Treatment of uncomplicated influenza A and B infections

Precise Products Predictable Effects Health Protection

OSELTAMIVIR

OSELTAMIVIR PHOSPHATE

Oseltamivir phosphate is a selective influenza virus neuraminidase inhibitor. By inhibiting the neuraminidase activity of influenza A and B viruses, it blocks the release of viruses from infected cells, thereby reducing viral transmission. A dry suspension is one of the three main dosage forms of oseltamivir (the other two are capsules and granules), and its advantages lie in its ease of administration and precise dosage adjustment.



Advantages

- Targeted antiviral mechanism against influenza viruses: It specifically inhibits neuraminidase, a key enzyme of influenza A and B viruses.
- Rapid alleviation of symptoms and shortened illness duration.
- Convenient oral suspension dosage form for special populations: The oral suspension formulation offers distinct advantages over tablets or capsules, particularly for patients who have difficulty swallowing solid dosage forms.
- Prophylactic efficacy in influenza outbreaks: It can be used for post-exposure prophylaxis in individuals who have had close contact with confirmed influenza patients.

Commonly used departments

- Pediatrics
- Respiratory Medicine
- Infectious Diseases

Strength

- 360 mg oseltamivir base supplied as powder (constituted to a final concentration of 6 mg/mL)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

KEHUANG CAPSULE

Kexing Biopharm

National patent-protected brand and an optimal medicine that specializes in curing heat, toxin, swelling and pain

Indications

- Heat clearing and detoxication;
- Stasis resolving and bind dissipating;
- Applicable to the pattern of retained damp-heat and pathogenic toxin and pattern of blood stasis obstructing the collaterals, such as distending pain of lateral thorax, hypochondriac lump, bitter sticky mouth, poor appetite and abdominal distension, yellow face and eyes, short and reddish urine, dark redness or ecchymosis and petechia on tongue, yellow greasy tongue coating, and slippery, string-like or rough pulse; as well as acute and chronic hepatitis.

Precise Products Predictable Effects Health Protection

KEHUANG

KEHUANG

Kehuang Capsule originated from the Shaolin Temple in Quanzhou of Fujian Province in 1867 (during the reign of Emperor Tongzhi in Qing Dynasty), and is mainly composed of precious medicinal materials such as She Xiang (Moschus), Niu Huang (Calculus Bovis), San Qi (Panax Notoginseng) and She Dan Zhi (Fel Serpentis). Back in 1927, pestilences, hepatitis and dyspepsia particularly, were raging in Quanzhou, and people found that Kehuang Capsule can achieve positive efficacy in curing these diseases. Hence Kehuang Capsule got its name. After these findings, Kehuang Capsule became popular among folks in the inland of southern Fujian and earned the trust of the masses.

Afterwards, Kehuang Capsule was introduced and inherited in Taiwan and Hong Kong, and was manufactured by Taiwan Oriental Traditional Chinese Medicine Company and Hong Kong Oriental Traditional Chinese Medicine Company. Later on, Kehuang Capsule became influential and popular in Southeast Asia, Europe, America, and Japan.

In 1989, our company started to cooperate with Taiwan Oriental Traditional Chinese Medicine Company to develop this brand. On one hand, we continued using the traditional fermentation technique; on the other hand, we conducted all related developmental work such as establishment of process specification, researches on pharmacology & toxicology and clinical studies. In September 1994, Kehuang Capsule received New Drug Certificate and was permit- ted to be manufactured. Since then, Kehuang Capsule has begun to revive in mainland China.

Strength

- 0.4g/capsule

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

SINGENSU
Entecavir Tablets

Kexing Biopharm

An anti-hepatitis B drug with the lowest drug resistance rate

Indications

• Chronic hepatitis B in adults with active viral replication, persistently elevated serum alanine aminotransferase (ALT), or active disease by liver histology.

Precise Products Predictable Effects Health Protection

SINGENSU

SINGENSU

SINGENSU, a guanine nucleotide analog, inhibits the reverse transcriptase of hepatitis B virus. It is currently the anti-hepatitis B drug with the lowest drug resistance rate as well as favorable safety and tolerability，and also recommended as the first-line antiviral drug in many authoritative guidelines for the diagnosis and treatment of hepatitis B worldwide.

Advantages

- It has passed the consistency evaluation of generic drugs;
- It has favorable safety and tolerability;
- It is recommended as the rst-line antiviral drug in many authoritative guidelines for the diagnosis and treatment of hepatitis B worldwide;
- It is the Top 1 product on the list of systemic antiviral drugs in public medical institutions in China.

Commonly used departments

- Hepatology

Strength

- 0.5 mg/tablet

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

EXINKIRA
Liraglutide Injection

Kexing Biopharm

A blockbuster drug in the field of diabetes, with significant hypoglycemic effect

Indications

Blood glucose control in adult patients with type 2 diabetes.

Precise Products Predictable Effects Health Protection

EXINKIRA

EXINKIRA

Liraglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist, which promotes insulin secretion based on blood glucose level, protects islet β cells, delays gastric emptying and reduces appetite. As an emerging new drug for diabetes treatment in recent years, it can effectively reduce blood glucose level, with low risk of hypoglycemia, which is indicated for blood glucose control in adult patients with type 2 diabetes.

Advantages

- The second liraglutide injection applied for marketing in China;
- Manufacturer: a leading manufacturer in the insulin field of China;
- Convenient medication: Only need to take medication once a day, without limiting the duration of administration;
- It not only has good hypoglycemic effect, but also has significant advantages such as weight loss, blood pressure reduction, and improving blood lipid profile.

Commonly used departments

- Endocrinology

Strength

- 3 mL: 18 mg (pre-filled)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

SITAGLIPTIN PHOSPHATE TABLETS

Kexing Biopharm

Oral hypoglycemic DPP-4 inhibitor

Indications

- This product is used as monotherapy in combination with diet control and exercise to improve glycemic control in patients with type 2 diabetes;
- This product is also used in combination with metformin, or in combination with sulfonylurea drugs (with or without metformin), or in combination with insulin (with or without metformin) to improve glycemic control in patients with type 2 diabetes who have poor glycemic control.

Precise Products Predictable Effects Health Protection

SITAGLIPTIN

Sitagliptin Phosphate is a oral anti-diabetic medication belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is widely used in the management of type 2 diabetes mellitus (T2DM) to improve glycemic control.

Advantages

Sitagliptin phosphate is a cornerstone therapy in T2DM due to its balanced profile of efficacy, safety, and convenience. Its glucose-dependent mechanism, minimal side effects, and adaptability to diverse patient needs make it a preferred choice for both monotherapy and combination strategies. Always individualize treatment based on patient-specific factors and clinical guidelines.

Commonly used departments

- Endocrinology
- Diabetes
- Endocrinology
- Geriatrics

Strength

- 25mg
- 50mg
- 100mg

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

OZELYDE
Semaglutide Injection

Kexing Biopharm

A once-weekly GLP-1 RA for efficient blood sugar reduction

Indications

Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as:

- An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus;
- To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Precise Products Predictable Effects Health Protection

OZELYDE

OZELYDE

Semaglutide is a powerful once-weekly GLP-1 agonist injection clinically proven for effective blood sugar control in type 2 diabetes and significant weight management.

Advantages

Semaglutide demonstrates exceptional efficacy in lowering blood glucose (HbA1c) in type 2 diabetes and promoting substantial weight loss. Its once-weekly dosing enhances convenience and adherence compared to daily alternatives. Furthermore, semaglutide provides proven cardiovascular benefits. Its combination therapy contains metformin and/or thiazolidinediones, metformin or metformin with sulfonylurea, basal insulin.

Commonly used departments

- Endocrinology
- Diabetes
- Metabolism
- Cardiovascular

Strength

- 1.34mg/ml, 1.5ml (0.25/0.5mg, pre-flled, disposable, single-patient-use pens)
- 1.34mg/ml, 1.5ml (1mg, pre-flled, disposable, single-patient-use pens)
- 1.34mg/ml, 3ml (pre-flled, disposable, single-patient-use pens)
- 2.68mg/ml, 3ml (pre-flled, disposable, single-patient-use pens)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ENZALUTAMIDE SOFT CAPSULES

Kexing Biopharm

A novel oral androgen receptor(AR) inhibitor

Indications

- Adult patients with nonmetastatic cachectic resistant prostate cancer (NM-CRPC) who are at high risk of metastasis;
- Treatment of asymptomatic or minimally symptomatic adult patients with metastatic chemorefractory prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and are not receiving chemotherapy;

Precise Products Predictable Effects Health Protection

ENZALUTAMIDE

Enzalutamide is a specific androgen receptor (AR) inhibitor. It can not only block the binding of androgens to the receptor but also inhibit the translocation of the receptor into the cell nucleus and the binding of the androgen receptor to DNA. Therefore, it is not only an androgen receptor antagonist but also inhibits the androgen signaling pathway.

Advantages

- Broad Spectrum of Activity Across Prostate Cancer Stages.
- Mechanistic Depth: Multi-Target Inhibition of Androgen Receptor (AR) Signaling;
- Manageable Safety Profile with Low Risk of Hormonal Side Effects.
- APIs and soft capsules have been approved for marketing in China and the United States.

Commonly used departments

- Urology
- Oncology
- Radiation

Strength

- 40mg/capsule

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

AFLIBERCEPT INTRAVITREOUS INJECTION

Kexing Biopharm

The world's best-selling anti VEGF ophthalmic drug



Indications

- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR) in Patients with DME

Precise Products Predictable Effects Health Protection

AFLIBERCEPT

AFLIBERCEPT

Aflibercept is a fully recombinant human fusion protein,it can bind to multiple VEGF family members (such as VEGF-A, VEGF-B, and placental growth factor PlGF) with high affinity, more broadly blocking pro-angiogenic signals and inhibiting the formation and leakage of new blood vessels. Especially in ocular fundus diseases, it shows significant effects in reducing macular edema and controlling the proliferation of new blood vessels.



Advantages

- It can simultaneously and powerfully bind to VEGF-A, VEGF-B and PlGF (placental growth factor), making the effect more comprehensive and lasting.
- In ophthalmic indications (such as wet age-related macular degeneration, diabetic macular edema, etc.), compared with some other anti-VEGF drugs, aflibercept has a longer duration of action. The dosing interval can be appropriately extended, reducing the frequency of injections and improving patient compliance and quality of life.

Commonly used departments

- Ophthalmology
- Oncology

Strength

- 4mg/0.1ml/Vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

DENOSUMAB

Kexing Biopharm

First line therapeutic drugs for osteoporosis (OP), New selection for patients with solid tumor bone metastasis

Indications

- Treatment of postmenopausal women with osteoporosis at high risk of fractures (60 mg(1.0 mL));
- Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity (120 mg(1.7 mL)).

Precise Products Predictable Effects Health Protection

DENOSUMAB

Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (Chinese hamster ovary cells) by recombinant DNA technology.



Advantages

- Selective Inhibition of RANKL: Directly blocks the RANKL-RANK pathway, a key driver of osteoclast activation and bone resorption;
- Spars Osteoblasts and Bone Formation: Unlike bisphosphonates, which affect both osteoclasts and osteoblasts, denosumab selectively targets osteoclasts, preserving bone-forming activity;
- Increases bone mineral density (BMD) and reduces fracture risk in postmenopausal women and men with high-risk osteoporosis.

Commonly used departments

- Oncology
- Orthopedics
- Endocrinology
- Hematology

Strength

- 60 mg(1.0 mL)
- 120 mg(1.7 mL)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

PROPOFOL INJECTABLE EMULSION

Kexing Biopharm

An intravenous anesthetic widely used in clinical practice, with the characteristics of rapid onset, short duration of action, and rapid recovery

Indications

Propofol 1% (10 mg/ml) is a short-acting intravenous general anaesthetic for

- Induction and maintenance of general anaesthesia in adults and children > 1 month
- Sedation of ventilated patients > 16 years of age in the intensive care unit
- Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > 1 month.

Precise Products Predictable Effects Health Protection

PROPOFOL

PROPOFOL

Propofol is an alkylphenol organic compound with the chemical name 2,6-diisopropylphenol and the chemical formula $C_{12}H_{18}O$. It is a fast-acting, potent intravenous anesthetic with rapid onset, smooth induction, short duration of action, rapid metabolism, no accumulation, and sedative and amnesic effects.

Advantages

- Rapid Onset and Offset: Induction of anesthesia occurs within approximately 30 seconds of intravenous injection. Recovery is equally swift, with patients typically waking up clearly within a few minutes after discontinuation of the infusion.
- Highly Titratable Sedative Effect: The depth of sedation and anesthesia can be precisely and smoothly controlled by adjusting the infusion rate, making it suitable for various surgical procedures and sedation needs.
- Favorable Safety Profile with Fewer Side Effects: It is rapidly metabolized primarily by the liver, with minimal impact on renal function. The incidence of postoperative nausea and vomiting is low.

Commonly used departments

- Anesthesiology
- Endoscopy Center
- ICU
- ED

Strength

- 10ml:100mg
- 20ml:200mg
- 50ml:500mg

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

SINGTEOS
Teriparatide Injection

Kexing Biopharm

The world's first drug to promote bone formation



Indications

- Treatment of postmenopausal women with osteoporosis at high risk for fracture.

Precise Products Predictable Effects Health Protection

SINGTEOS

Teriparatide is a synthetic peptide hormone, a 1-34 amino acid fragment of human parathyroid hormone (PTH).

Teriparatide is the world's first marketed bone-forming drug. It effectively improves bone microarchitecture and increases bone strength, while promoting bone healing and reducing the risk of vertebral and non-vertebral fractures. It is an ideal treatment for osteoporosis and is recommended by national and international guidelines.



Advantages

- Unique mechanism of action for active bone formation: Teriparatide (a recombinant fom of human parathyroid hormone fragment) acts as an anabolic agent.
- Significant reduction in fracture risk: Clinical evidence confirms that teriparatide effectively lowers the riskof fractures in high-risk populations.In patients with glucocorticoid-induced osteoporosis or male osteoporosis, it also demonstrates a clear protective effect against fractures
- Favorable efficacy in refractory or high-isk cases: t shows remarkable therapeutic value in patients who have faled to respond to conventional ant*resorptive therapies (e.g., bisphosphonates) or cannot tolerate such treatments due to side effects
- Good tolerability and manageable safety profile.

Commonly used departments

- Orthopedics
- Gynecology
- Geriatrics

Strength

- 20μg: 80μl, 2.4ml/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

TAMSULOSIN HYDROCHLORIDE CAPSULES

Kexing Biopharm

First-line drugs in clinical urology

Indications

- Treatment of urination disorders caused by benign prostatic hyperplasia (BPH)

Precise Products Predictable Effects Health Protection

TAMSULOSIN

TAMSULOSIN

Tamsulosin is a commonly used drug in urology, widely used for lower urinary tract symptoms (LUTS), ureteral stones, and men's health problems.
It is a highly selective, long-acting α1 adrenergic receptor blocker. It works by blocking the binding of α1 receptors to neurotransmitters (such as norepinephrine) in certain locations (such as the prostate, bladder neck, urethra, and ureters), thereby inhibiting α1 receptor-mediated smooth muscle contraction and alleviating symptoms.

Advantages

- Targeted action on the lower urinary tract: Addressing the root cause of voiding symptoms in prostate-related conditions, rather than just alleviating symptoms superficially.
- Rapid relief of urinary symptoms: It demonstrates a relatively fast onset of action.
- Minimal impact on blood pressure: Compared to non-selective α1-adrenergic blockers, tamsulosin's high selectivity for the α1A subtype.
- Oral capsule formulation for convenient adherence.

Commonly used departments

- Urology
- Andrology
- Geriatrics

Strength

- 0.4 mg/capsule

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

NINTEDANIB ESILATE SOFT CAPSULES

Kexing Biopharm

The only two approved and guideline-recommended drugs for the treatment of idiopathic pulmonary fibrosis (IPF) in the world



Indications

- Idiopathic Pulmonary Fibrosis (IPF)
- Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype

Precise Products Predictable Effects Health Protection

NINTEDANIB

NINTEDANIB

As a multi-target tyrosine kinase inhibitor, nintedanib inhibits the activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR), inhibiting fibroblast proliferation and inflammatory response, thereby slowing the progression of pulmonary fibrosis.



Advantages

- Dual mechanism targeting fibrosis and vascular dysfunction.
- Broad efficacy across multiple progressive fibrotic lung diseases: Unlike some drugs limited to a single indication, nintedanib demonstrates consistent efficacy in several types of progressive fibr3.Proven reduction in lung function decline: Clinical trials consistently confirm that nintedanib slows the rate of forced vital capacity (FVC) decline—a key marker of lung function loss in fibrotic ILDs.otic interstitial lung diseases (ILDs).
- Proven reduction in lung function decline: Clinical trials consistently confirm that nintedanib slows the rate of forced vital capacity (FVC) decline—a key marker of lung function loss in fibrotic ILDs.
- Favorable safety profile for long-term use.
- Oral administration for improved patient adherence.

Commonly used departments

- Respiratory and Critical Care Medicine
- Pulmonology (in specialized ILD Centers)
- Rheumatology and Immunology

Strength

- 100mg
- 150mg

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com